AgomAb Therapeutics NV American Depositary Shares (AGMB) — Defensive Interval Ratio
AgomAb Therapeutics NV American Depositary Shares (AGMB) has a Defensive Interval Ratio of 81 days as of March 2026. Defensive assets of $2.12 Million (cash $-, short-term investments $-, receivables $2.12 Million) cover 81 days of daily cash needs of $26.05K/day. Check AgomAb Therapeutics NV American Deposita tangible book value ratio to evaluate the tangible quality of the company's equity base.
Defensive Interval Ratio
Defensive Assets
Daily Cash Need
Current Liabilities
AgomAb Therapeutics NV American Depositary Shares Defensive Interval Ratio (2021–2025)
This chart shows how AgomAb Therapeutics NV American Depositary Shares's Defensive Interval Ratio has evolved across 5 annual periods from 2021 to 2025. As of March 2026, the ratio stands at 81 days, meaning defensive assets of $2.12 Million can fund 81 days of operations without new revenue. Also explore net asset growth rate of AgomAb Therapeutics NV American Deposita to track the company's year-over-year net asset growth rate.
Annual Defensive Interval Ratio for AgomAb Therapeutics NV American Depositary Shares (2021–2025)
The table below presents the year-by-year Defensive Interval Ratio for AgomAb Therapeutics NV American Depositary Shares from 2021 to 2025, covering 5 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. For live market cap and the full company financial profile, see AGMB market cap overview.
| Year | DIR (days) | Defensive Assets (USD) | Daily Cash Need | Cash | ST Investments | Change (days) |
|---|---|---|---|---|---|---|
| 2025 | 591 days | $30.10 Million | $50.93K/day | $- | $30.10 Million | ▲ +591 days |
| 2024 | 0 days | $0.00 | $25.00K/day | $- | $0.00 | ▲ +0 days |
| 2023 | 0 days | $0.00 | $29.82K/day | $- | $0.00 | ▼ -491 days |
| 2022 | 491 days | $40.00 Million | $81.41K/day | $- | $40.00 Million | ▲ +491 days |
| 2021 | 0 days | $0.00 | $92.35K/day | $- | $0.00 | — |